John Meady

Credit Suisse Reports a Strong First Quarter

Credit Suisse CS earned CHF 1,026 million (CHF 0.76 per diluted share) in the first quarter compared with CHF 41 million in the year-ago quarter and CHF 221 million in the trailing quarter on better trading results and lower expenses. This quarter’s reported profit, which included CHF 80 million of noncash own-debt losses, amounted to…

Read More

Why Need to Watch – 3M Co (NYSE:MMM) , Camden Property Trust (NYSE:CPT) , Travelzoo Inc. (NASDAQ:TZOO) , Hampton Roads Bankshares, Inc. (NASDAQ:HMPR)

3M Co (NYSE:MMM) will pay about $885 million for Sumitomo Electric Industries Ltd’s stake in their Japan joint venture, giving the diversified U.S. manufacturer full control of the business, 3M said on Wednesday. The deal is expected to add about 8 cents per share to earnings in the first 12 months after it closes, 3M…

Read More

Kirby’s Coastal Operations Continue to Improve in the First Quarter

Kirby’s KEX first-quarter revenue fell 1% from last year. The decline was driven by anemic demand for United’s pressure pumping units, tempered by solid inland trends and improvement in coastal operations. The marine transportation business (75% of first-quarter sales) saw revenue increase 25%, thanks to persistent petrochemical and crude oil shipment demand, which is supporting…

Read More

Momentum Stocks – Goldman Sachs (NYSE:GS) , Tel-Instrument Electronics Corp. (NYSEMKT:TIK) , Marsh & McLennan Companies, (NYSE:MMC) , Simpson Manufacturing Co, Inc. (NYSE:SSD)

Data signaling strength in the world’s largest economy prompted Goldman Sachs Group Inc. (NYSE:GS) to push forward its forecast for when Fed will raise interest rates to the third quarter of next year rather than the first three months of 2016. Goldman Sachs Group Inc (NYSE:GS) stock performance was 1.33% in last session and finished…

Read More

Stocks to Watch – Celladon Corp (NASDAQ:CLDN), West Marine (NASDAQ:WMAR), Avnet (NYSE:AVT) , ChinaCache Internatnl Hldgs Ltd (ADR) (NASDAQ:CCIH)

Celladon Corporation (NASDAQ:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, on 07 July 2014 announced it has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF)…

Read More